Valuation

RPRXRoyalty Pharma plc

StockNasdaqUnited StatesHealth careEU retail: available

−0.7% today · +81.5% over a year

6/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 90% of the instruments we score

Quality, Trend, Stability: among the best of its peers. Dividend yield 1.43%.

Royalty Pharma plc (RPRX) valuation against sector peers: P/E 44.3 (sector median 30.6), P/B 3.7, EV/EBIT 31.2, P/S 14.2.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricRPRXSector medianvs median
P/E44.330.6 · n=15245% above
P/B3.74.0 · n=3058% below
P/S14.24.4 · n=297221% above
EV/EBIT31.225.8 · n=13921% above
Free-cash-flow yield—1.4% · n=287—
Dividend yield1.43%0.00% · n=358—
Return on equity8.5%−3.7% · n=306—
Return on invested capital8.7%0.4% · n=2751,891% above
Gross margin—61.7% · n=202—
Net debt / EBITDA5.361.31 · n=146309% above

Value factor: 59 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

LLYEli Lilly & Co45.435.8—1.5%0.6%7/10
JNJJohnson & Johnson40.58.0—3.2%1.9%8/10
ABBVAbbVie80.6—33.83.6%3.0%5/10
UNHUnitedHealth25.93.519.16.5%2.2%9/10
MRKMerck109.68.3—4.6%2.4%9/10
TMOThermo Fisher Scientific37.44.936.72.8%0.3%10/10
AMGNAmgen27.920.925.24.2%2.2%7/10
GILDGILEAD—16.7—6.6%2.0%5/10
ABTAbbott28.43.426.84.1%3.0%6/10
PFEPfizer38.72.0—6.5%7.3%1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Jun 2026 · filed 05 Aug 2026